Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 196Nivolumab 57Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × aflibercept × 90 days × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡